Voyager Therapeutics (VYGR)

Executive Summary

Voyager Therapeutics is a clinical-stage biotechnology company pioneering next-generation gene therapies for severe neurological diseases. Its core innovation is the TRACER™ platform, which engineers novel AAV capsids capable of crossing the blood-brain barrier after intravenous infusion, potentially revolutionizing CNS drug delivery. The company is advancing a focused pipeline targeting Alzheimer's disease, ALS, and Parkinson's disease. Voyager's lead candidate, VY7523, is in a Phase 1/2 trial for Alzheimer's disease, with the trial initiated in March 2025 and expected to complete in May 2027. The company's market cap is approximately $242 million, reflecting its early-stage status but significant potential if the TRACER platform proves clinically viable. Voyager's strategy includes leveraging its capsid discovery platform to create differentiated gene therapies and pursuing partnerships to broaden the impact of its technology.

Upcoming Catalysts (preview)

• Q3 2026Interim Data from Phase 1/2 Trial of VY7523 in Alzheimer's Disease60% success
• Q2 2026TRACER Platform Update: New Capsid or Preclinical Data70% success
• TBDPotential Partnership or Licensing Deal for TRACER Platform40% success